DARWIN EU: The Go-To Place For Real World Data
An EU-wide network of real-world data sources will aim to become the dominant vehicle for delivering such evidence to the EMA and member countries, who have until now been using a wide range of different sources to access such data.
You may also be interested in...
High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies
Within one year of its establishment, DARWIN EU has started reaping benefits for EU drug regulators commissioning studies using real-world data to better understand diseases, populations and the uses and effects of medicines. The studies can be performed faster, cheaper and at increased capacity.
EMA, HTA Bodies & Payers Explore Common Ground On Use Of RWE
A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers.
EU Health Data Project: More Use Of Real-World Evidence In Price Negotiations
The proposed European Health Data Space is expected to boost innovation in preventing, diagnosing and treating disease and to support the long-term competitiveness of the EU’s medical sector. The pharmaceutical industry has broadly welcomed the move but wants to see certain safeguards and guarantees put in place.